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Abstract 
Piperazine-based drugs, such as N-benzylpiperazine (BZP), became attractive in the 2000s due to 
possessing effects similar to amphetamines. Herein, BZP, in addition to its pyridyl analogues, 2-, 3- 
and 4-pyridylmethylpiperazine (2-PMP, 3-PMP and 4-PMP respectively) were subjected to the 
hyperpolarisation technique SABRE (Signal Amplification By Reversible Exchange) in order to 
demonstrate the use of this technique to detect these piperazine-based drugs. Although BZP was 
not hyperpolarised via SABRE, 2-PMP, 3-PMP and 4-PMP were, with the ortho- and meta-pyridyl 
protons of 4-PMP showing the largest enhancement of 313-fold and 267-fold respectively in a 1.4 T 
detection field, following polarisation transfer at earth’s magnetic field. In addition to the freebase, 
4-PMP.3HCl was also appraised by SABRE and was found not to polarise, however, the addition of 
increasing equivalents of triethylamine (TEA) produced the freebase, with a maximum enhancement 
observed upon the addition of three equivalents of TEA. Further addition of TEA led to a reduction in 
the observed enhancement. SABRE was also employed to polarise 4-PMP.3HCl (ca. 20% w/w) in a 
simulated tablet to demonstrate the forensic application of the technique (138-fold enhancement 
for the ortho-pyridyl protons). The amount of 4-PMP.3HCl present in the simulated tablet was 
quantified via NMR using D2O as a solvent and compared well to complimentary GC-MS data. 
Exchanging D2O for CD3OD as the solvent utilised for analysis resulted in a significantly lower amount 
of 4-PMP.3HCl being determined, thus highlighting safeguarding issues linked to drug abuse in 
relation to determining the amount of active pharmaceutical ingredient present. 
Introduction 
Utilisation of hyperpolarization techniques to overcome the inherent sensitivity issue that is 
associated with Nuclear Magnetic Resonance (NMR), and by extension, Magnetic Resonance Imaging 
(MRI), is well documented.[1] The inherent insensitivity associated with both of these techniques 
arises due to the small population differences of the energy states that it probes. Parahydrogen 
induced polarization (PHIP)[2] is one of many hyperpolarisation techniques that has been employed 
to circumvent the inherent insensitivity of NMR and MRI through the creation of non-Boltzmann 
distributions of nuclear spins in the molecule(s) of interest.  
PHIP utilises parahydrogen, a spin-isomer of hydrogen, as the source of polarisation.[3] As 
parahydrogen is a nuclear singlet, it is NMR silent and to gain access to the polarised state, its 
symmetry must be broken.[4] To achieve this, PHIP makes use of a metal centred catalyst, which 
catalyses the hydrogenation of a target ligand. Thus, polarisation is transferred to the target ligand 
resulting in dramatically increased signals in the NMR spectrum or MR image. However, this process 
does necessitate the chemical transformation of the target ligand, and as such, they must be 
chemically synthesised to possess functional groups that can undergo hydrogenation.  
An established non-hydrogenative parahydrogen-based technique is Signal Amplification By 
Reversible Exchange (SABRE), first reported in 2009.[5] Target ligands for this technique are largely 
limited to N-heterocycles, although there is increasing evidence of alcohols,[6] amines[7] and 
phosphates[7b] being able to be polarised by this technique. 1H,[5, 7-8] 13C,[9] 15N,[10] 19F,[11] 31P,[7b, 12] 29Si 
and 119Sn[13] are all nuclei that have been polarised using the technique. An iridium-centred catalyst 
is typically employed to propagate polarisation, although examples of cobalt complexes have also 
been reported.[14] Polarisation is transferred from parahydrogen-derived hydrides and target ligand 
spin ½ nuclei via J-coupling,[15] with polarisation transfer occurring optimally at a level anti-
crossing.[16] Polarisation transfer can be facilitated at low-magnetic field or at high-magnetic field, 
the latter being possible only through the use of specialised sequences.[17] The pre-catalyst, 
[Ir(IMes)(COD)Cl] (IMes = 1,3-bis(2,4,6-trimethylphenyl)imidazole-2-ylidene, COD = cyclooctadiene) 
has been shown to be an excellent catalyst, following activation, for facilitating polarisation transfer. 
Methyl-4,6-d2-nicotinate has been polarised to a level of 50% using [Ir(IMes-d22)(COD)Cl] as the pre-
catalyst.[18]  
A large number of studies have focused on pyridine,[5, 8c, 9b, 9c, 17, 19] which is not biologically relevant. 
Thus, a number of drug molecules have been polarised by SABRE to not only study polarisation 
transfer but also to collect MR images of phantoms. Nicotinamide, a form of vitamin B3, has been 
investigated using SABRE to probe the physical constraints and the population of spin order terms 
through the use of a flow system,[20] to relay polarisation to a second metal complex in solution[21] 
and to obtain MR images.[17, 22] Other examples of drugs that have been polarised and studied using 
SABRE include the tuberculosis drugs isoniazid and pyrazinamide,[8b, 23] the anti-fungal drug 
voriconazole[11c], the antibiotic metronidazole[10c, 24] and dalfampridine (4-aminopyridine),[25] which is 
used to study potassium channels and manage symptoms associated with multiple sclerosis. The use 
of SABRE in detecting drugs, such as harmine and morphine, down to the micromolar regime has 
been reported, as has the use of SABRE to detect selectively pyridyl fentalogues against a heroin 
background.[26] 
Herein, the focus is to polarise N-benzylpiperazine (BZP) and its pyridyl derivatives, 2-, 3- or 4-
pyridylmethylpiperazine (2-PMP, 3-PMP or 4-PMP respectively, Figure 1). BZP is a recreational drug 
that rose to prominence due to the growing popularity of 3,4-methylenedioxymethamphetamine 
(MDMA, Ecstasy), which influenced an influx of similarly structured compounds known as 
piperazines.[27] BZP became the most popular MDMA/amphetamine substitute, with most of its 
distribution found in New Zealand (under the name BZP party pills), however, BZP has also been 
detected in the UK, Brazil and Japan.[27b, 28] The attractive euphoric effects saw them become 
prominent on the club scene as a safer alternative to MDMA, with an estimated 8 million doses sold 
between 2000 and 2005 in New Zealand.[27b] 
  
 
Figure 1. Chemical structures of BZP, 2-, 3- and 4-PMP 
This paper details the employment of SABRE to hyperpolarise BZP and the PMP derivatives in both 
their hydrochloride and freebase forms utilising benchtop NMR (60 MHz) for detection. The PMP 
derivatives are pyridyl analogues of BZP and as such, could be synthesised by clandestine 
laboratories to circumvent current legislation. Thus, although 2-, 3- and 4-PMP have not been 
reported as being abused recreationally, they represent future potential forensic targets. An 
emphasis is placed on the detection of 1H polarisation only. The effect of the addition of base 
(triethylamine (TEA)), on the enhancement observed for both freebase and hydrochloride forms of 
4-PMP.3HCl is examined. Lastly, the extraction, and subsequent hyperpolarisation and 
quantification, of 4-PMP.3HCl from a simulated pill is detailed, in order to highlight how the 
approach could be applied to forensic casework.  
Experimental 
2, 3 and 4-PMP freebase were purchased from Fluorochem Ltd. (Hadfield, UK) and were used 
without further purification. BZP.2HCl was purchased from Sigma-Aldrich. Solvents (Sigma-Aldrich, 
Gillingham, UK and Fisher Scientific, Loughborough, UK) were used as received. 1H NMR and 13C NMR  
spectra utilised for the characterisation of 4-PMP.3HCl were acquired on a JEOL ECS-400 (JEOL, 
Tokyo, Japan) NMR spectrometer operating at a 1H resonance frequency of 400 MHz and referenced 
to the residual OH peak of D2O (δ = 4.79). Hyperpolarisation studies were conducted on an bench-
top Pulsar NMR spectrometer (Oxford Instruments, Oxford, UK) operating at a 1H resonance 
frequency of 60 MHz and referenced to the residual methyl solvent peak of CD3OD (δ = 3.33). 
1-(4-Pyridylmethyl)piperazine hydrochloride (4-PMP.3HCl) was prepared by treating a solution of 1-
(4-pyridylmethyl)piperazine (0.5 g, 2.82 mmol) in diethyl ether (10 mL) with 4 M HCl in dioxane (5.6 
mL, 11.2 mmol, 4 eq.). The resulting powder was collected by filtration and washed with diethyl 
ether (2 x 5 mL). The crude product was purified by recrystallisation from acetone to give the target 
compound as a beige powder (0.81 g, 100%); 1H NMR (400 MHz, D2O) δ 8.91 (d, 2H, J = 6.02 Hz, 
ortho-pyridyl protons), 8.26 (d, 2H, J = 6.02 Hz, meta-pyridyl protons), 4.58 (s, 2H, CH2), 3.57 (t, 4H, J 
= 5.02 Hz, piperazine CH2), 3.46 (t, 4H, J = 5.02, piperazine CH2); 13C{1H} NMR (100 MHz, D2O) δ 154.7 
(Cquat pyridyl), 144.85 (Cortho pyridyl), 131.70 (Cmeta pyridyl), 61.75 (CH2), 51.48, 44.48 (CH2 piperazine).  
SABRE measurements were conducted as follows: the substrate to be polarised (5 equivalents, 
1.5x10-5 mol) and the pre-catalyst ([Ir(IMes)(COD)Cl], 0.0031 mmol) were dissolved in d4-methanol 
(600 μL). If TEA was required, then this was added to the substrate prior to the addition of the pre-
catalyst. The amount of d4-methanol was also reduced to maintain a volume of 600 μL. The resulting 
solutions were then taken up by syringe and transferred into a NMR tube equipped with a Young’s 
tap. The sample was then degassed on a high-vacuum line via three ‘cool’-pump-thaw cycles (using a 
acetone/CO2 slush bath). Parahydrogen, at a pressure of 3.0 atmospheres was then admitted to the 
NMR tube. Parahydrogen was produced by cooling hydrogen gas to 77 K over charcoal.[29] The 
sample was then shaken to form the catalytically active species in solution prior to collecting a 
thermal 1H NMR spectrum. Complete activation occurred within ~5 min and was evidenced by a 
single hydride signal being observable at ca. δ –23. For the collection of SABRE measurements, the 
hydrogen in the head-space of the tube was replenished with parahydrogen prior to shaking for 10 s 
in earth’s magnetic field (ca. 0.05 mT). The sample was then rapidly inserted in to the NMR 
spectrometer and a 1H NMR spectrum acquired using a π/2 pulse.  
SABRE-relay measurements were conducted as follows: the substrate to be polarised (4 equivalents, 
1.2x10-5 mol) was solvated in D2O (500 μL) and ammonia (100 μL, 35% in H2O) to which was added 
the pre-catalyst ([Ir(IMes)(COD)Cl], 0.0031 mmol). The sample was shaken to ensure full ligand and 
pre-catalyst solvation before transfer into a Young’s capped NMR tube. The sample was then 
degassed as described above, with the exception that the sample was immersed in liquid nitrogen 
instead of an acetone/CO2 slush bath. 
The simulated tablet (522.5 mg) consisted of 4-PMP.3HCl (106.9 mg) and hydroxypropyl 
methylcellulose (HPMC, 415.6 mg). The tablets were made using an adaptation of the procedure 
reported by Hamad et al.[30] For the analysis of the tablet via SABRE, 30 mg of the tablet (containing 
ca. 6 mg of active pharmaceutical ingredient) was added to 900 𝜇𝜇L of CD3OD prior to filtering 
through a through a 0.45 μm polyvinylidene difluoride syringe filter (Whatman). 300 𝜇𝜇L of the 
resulting filtered solution was added to a vial prior to the addition of 3 equivalents of TEA (3 𝜇𝜇L), 150 
𝜇𝜇L catalyst stock solution (6.66 mg mL-1) and 147 𝜇𝜇L CD3OD. The sample was then subjected to 
SABRE, as detailed in the paragraph above. For the quantification of the tablet by NMR, a weighed 
amount of the tablet (ca. 5 mg) was dissolved in CD3OD (1 mL) and TEA (12 𝜇𝜇L) or D2O (1 mL) and 
then analysed.  
Results and discussion 
Initially, BZP was selected for polarisation using SABRE given its reported use as a recreational drug. 
BZP was available commercially as the di-hydrochloride salt, and it was in this form that it was 
subjected to SABRE. Following exposure of parahydrogen to a methanolic solution containing 
BZP.2HCl and the pre-catalyst [Ir(IMes)(COD)Cl], 1, no polarisation transfer was observed. 
Furthermore, the lack of a hydride signal in the 1H NMR spectrum and retention of the yellow colour 
of the [Ir(IMes)(COD)Cl] inferred that activation of the catalyst had not occurred. This was expected, 
as the lack of suitable atoms for ligation to the hydrochloride form meant the required J-coupling 
network could not be established. Thus, BZP.2HCl was further examined in two further experiments 
in which 1.2 equivalents or 2 equivalents of TEA was utilised in order to either partially or completely 
freebase the ligand respectively. Resultant SABRE-based experiments again yielded no 
hyperpolarisation. It is likely that in order to hyperpolarise this molecule, especially as it possesses a 
piperazine ring rather than an N-heterocycle, SABRE-relay[6-7, 21] may need to be employed in order 
to facilitate polarisation.  
Our attention then turned to the 2-, 3- and 4-PMP ligands in their freebase forms. The applicability 
of SABRE to polarise 4-PMP was assessed using 1. A sample consisting of 4-PMP and 1 in a ratio of 
5:1 was constituted in CD3OD. Upon the addition of hydrogen, the sample became colourless and a 
single hydride was evident at δ –22.80. Similar chemical shifts have been reported for the hydride 
ligand for a range of different [Ir(NHC)(COD)Cl] complexes when pyridine is the ligand due to the 
formation of [Ir(NHC)(pyridine)3(H)2]+.[31] In this instance, the presence of a single hydride results 
from symmetry in the complex, due to the formation of [Ir(IMes)(4-PMP)3(H)2]+ (Figure 2). There was 
no evidence for the formation of [Ir(IMes)(4-PMP)2(H)2(CD3OD)]+ or [Ir(IMes)(4-PMP)2(H)2(Cl)] unlike 
previous reports concerned with pyridine.[32] 
 
Figure 2. Chemical structure of [Ir(IMes)(4-PMP)3(H)2]+ 
Charging this sample with parahydrogen followed by polarisation transfer in earth’s magnetic field 
(0.5 x10-4 T) provided evidence for SABRE-based hyperpolarisation having occurred (Figure 3). As a 
result of polarisation transfer, the ortho-pyridyl protons were enhanced by 313-fold, and provided 
an emission signal. Similarly, the meta-pyridyl protons were enhanced by 267-fold, but were 
observed as an absorption signal. The 4-PMP ligands bound to the catalyst (trans- to hydride) were 
also clearly evidenced following polarisation transfer at earth’s magnetic field. Although we note the 
observed enhancement could be improved by using different magnetic field strengths, earth’s 
magnetic field was chosen to provide a common magnetic field strength for polarisation transfer for 
all BZP and PMP derivatives tested herein.  
 
Figure 3. 1H NMR spectra collected at 1.4 T of 4-PMP (0.025 M) after hyperpolarisation transfer at 
earth’s magnetic field in the presence of 1 and parahydrogen (spectrum A) and the same sample 
that is fully relaxed sample (spectrum B). The thermal trace has been enlarged by a factor of 50 
relative to the hyperpolarised trace. The peaks marked α and β refer to the ortho- and meta-pyridyl 
1H nuclei of 4-PMP respectively. Signals marked with an * indicate ortho- and meta-pyridyl 1H signals 
for bound 4-PMP ligands trans- to hydride.  
Exchanging 4-PMP for 3-PMP and 2-PMP did not yield the same levels of enhancement. 3-PMP 
produced an enhancement that was two orders of magnitude lower than 4-PMP (ε = 8-fold for the 
ortho-pyridyl protons) whereas 2-PMP yielded negligible enhancement (the signal for the ortho-
pyridyl 1H was observed to be in emission). Steric hindrance surrounding the pyridyl binding site 
could be a major contributing factor as to why these compounds possessed limited enhancement via 
SABRE. Thus, the focus of future studies was directed towards 4-PMP.  
As the polarisation of 4-PMP via SABRE was successful, attention then turned to the polarisation of 
4-PMP.3HCl. The reason for wanting to study this hydrochloride salt is because many drugs are 
formulated in their salt form, rather than as the freebase, to facilitate pharmaceutical processing 
and aqueous solubility. Attempts to polarise this salt using the same methodology as 4-PMP did not 
result in polarisation transfer. The reason for this is that there are no donors available to ligate to 
the metal centre (due to the nitrogen atoms not being in their freebase form) and hence polarisation 
cannot be transferred via scalar coupling as none are established. Thus, 4-PMP.3HCl was partially 
free-based using triethylamine (TEA) in situ, prior to the addition of the pre-catalyst. TEA was 
selected because of the solubility of its hydrochloride salt in methanol. Only 1.2 equivalents of TEA 
was added because it was desired, initially, to only partially freebase the ligand. As the pyridine ring 
nitrogen is the least basic in that pKb for pyridine is 8.8 whereas the pKb of piperazine is 4.19, it was 
envisaged that this approach would enable ligation to the SABRE catalyst through the pyridyl ring 
primarily in order to facilitate polarisation transfer. Polarisation transfer in earth’s magnetic field 
resulted in an enhancement of ~8 fold for the ortho-pyridyl protons, which is a significant decrease 
compared to the free-base form of 4-PMP.  
To investigate further the effect of TEA on hyperpolarisation, 1.2 equivalents of TEA was added to a 
methanolic solution of freebased 4-PMP, prior to the addition of 1. Resultant polarisation transfer in 
earth’s magnetic field yielded only a 161-fold enhancement – roughly half the enhancement 
observed for the same experiment conducted in the absence of TEA. The presence of TEA in this 
experiment is clearly detrimental to SABRE. In a separate experiment, parahydrogen was introduced 
to a methanolic solution containing 4-PMP freebase and 1. The sample demonstrated SABRE as 
previously with the ortho-pyridyl protons being enhanced to a similar enhancement as before (300-
fold obtained compared to 313-fold previously). The 13-fold difference in enhancement is due to the 
manual shaking method employed here; a ±20% variation in enhancement values has been reported 
for the same sample when analysed by different experimenters.[20] Five equivalents of TEA was then 
added, and after the sample was degassed and placed under a parahydrogen atmosphere, the 
sample now displayed no SABRE activity at all – polarisation transfer had ceased. The basicity of TEA 
(pKb = 3.38) compared to the pyridyl moiety of 4-PMP means that TEA is by far the more competitive 
ligand for the SABRE catalyst employed. The lack of access to the metal centre means that 
polarisation transfer can no longer be transferred to 4-PMP and hence the resulting NMR spectrum 
shows no hyperpolarisation of this substrate. This also coincides with the loss of the hydride signal 
observed at δ –22.80 due to lack of exchange with parahydrogen.  
Given this observation, the number of equivalents of TEA utilized to free-base 4-PMP.3HCl was then 
probed. A series of solutions were prepared to produce an equivalence range of TEA, relative to 4-
PMP.3HCl, of 0-10 relative equivalents. The normalised results from this study are shown graphically 
in Figure 4. In the absence of TEA, there is no evidence of hyperpolarisation via SABRE following 
polarisation transfer in earth’s magnetic field. As the number of equivalents of TEA is increased, the 
enhancement of the ortho-pyridyl protons increases, reaching a maximum at three equivalents. This 
is to be expected given that 4-PMP.3HCl has been completely converted to 4-PMP at this point. A 
signal enhancement of 363-fold is observed at this equivalence, and this is comparable to the value 
obtained when 4-PMP freebase was examined, in the absence of TEA, taking in to account the 
experimental error associated with the measurement. Further addition of TEA, however, leads to a 
decrease in signal enhancement. This is again due to competition between TEA and 4-PMP for metal 
binding sites, of which the former is significantly more favoured. After the addition of four 
equivalents of TEA, the signal enhancement fell to 200-fold. Again, this is comparable to the drop in 
signal enhancement when 1.2 equivalents of TEA was added to 4-PMP freebase. Further addition of 
TEA causes the enhancement to drop to 20-fold when 10 equivalents have been added. It is 
noteworthy that the addition of TEA does not seem to change the species responsible for 
polarisation transfer as the main hydride present at δ −22.80 persists regardless of the concentration 
of TEA added.  
 
Figure 4. Normalised signal enhancement plotted against the equivalents of TEA added (relative to 4-
PMP.3HCl) for 4-PMP.3HCl and 4-PMP. 
In a further investigation, in which the enhancement of 4-PMP was monitored against increasing 
concentration of TEA, an expected decrease in signal was observed. When this data is normalised 
and contrasted with that of the analogous data for 4-PMP.3HCl, the slopes are in very good 
agreement. However, it should be noted that the level of signal enhancement after the addition of 7 
equivalents of TEA (equivalent to 10 equivalents of TEA added to 4-PMP.3HCl) results in effectively 
negligible signal enhancement (ca. ≤ −1-fold). This difference is significant and may be due to the 
large difference in the concentration of chloride. Iali and co-workers have reported that for the 
hyperpolarisation of pyrazine by SABRE, large differences in the signal intensity can be obtained 
when not only varying the ratio of CDCl3:D2O but also the identity of the salt additive used to 
increase phase transfer.[33] It is reported that for a sample consisting of pyrazine dissolved in 200 
𝜇𝜇L:400 𝜇𝜇L CDCl3:D2O that, after polarisation transfer at 3 mT, an enhancement of 690-fold is 
obtained. The addition of 0.0170 mmol NaCl leads to an increase in enhancement to 780-fold. It 
should be noted, however, that for other solution of differing ratios of CDCl3:D2O, but the same 
concentration of NaCl, the presence of NaCl had either no effect or was detrimental in terms of the 
enhancement observed. Knecht and co-workers have identified chloride as being able to re-bind to 
the main complex responsible for the polarisation of pyridine, [Ir(IMes)(pyridine)(H)2]+, through the 
implementation of chemical exchange saturation transfer (CEST).[32] This chloride complex, 
[Ir(IMes)(Cl)(d5-pyridine)2(H)2], was shown to be largely responsible for shortening the nuclear 
singlet lifetime of the parahydrogen-derived hydride protons; removal of chloride from solution, and 
thus [Ir(IMes)(Cl)(d5-pyridine)2(H)2] also, caused the nuclear singlet lifetime to increase by an order 
of magnitude. A similar effect could be occurring here, and may account for the difference in 
enhancements observed between samples of 4-PMP.3HCl and 4-PMP. 
Extrapolation of the technique to a simulated pill sample 
As BZP.2HCl could not be hyperpolarised by utilising the method employed herein, a simulated 
street sample was prepared and analysed, in which the API was 4-PMP.3HCl. There is no current 
data on 4-PMP.3HCl being abused, and as such, this approach merely sought to demonstrate the 
applicability of applying SABRE to detect the API in a tablet. The procedure for hyperpolarisation 
needed to be adapted to include a filtration step prior to the addition of TEA. This was required to 
remove the insoluble binder (hydroxypropyl methylcellulose, HPMC) used in the formation of the 
tablet. The amount of TEA added was based on that fact that the tablet comprised of ~100 mg of 4-
PMP.3HCl. Following polarisation transfer in earths’ field, an enhancement of 138-fold was obtained 
for the ortho-pyridyl protons of 4-PMP (Figure 5). The enhancement is lower than previously stated 
and this is because the amount of 4-PMP present in the sample is only ca. 2 mg, instead of ca. 4.5 
mg for the other 4-PMP.3HCl samples investigated herein. This process highlights the ability of the 
method to detect a low amount of API, following an extraction process to remove binder / filler 
material of the tablet. The downside of this approach is that the amount of API in the tablet must be 
known, so that the appropriate amount of TEA can be added; excess TEA would decrease the 
enhancement observed, whereas too little TEA would result in no enhancement at all. GC-MS (gas 
chromatography-mass spectrometry) was employed to also analyse the tablet prepared, which 
identified 4-PMP.3HCl as being the sole component present (Rt = 5.913 mins) from the 
chromatogram, with the eicosane internal standard possessing a Rt of 7.223 mins. Quantitative GC-
MS analysis of the tablet revealed that the tablet consisted of either 111.8 mg or 107.5 mg of 4-
PMP.3HCl after being analysed with or without an internal standard (eicosane). This compares well 
with the measured amount (106.9 mg).  
 
Figure 5. 1H NMR spectra collected at 1.4 T of 4-PMP.3HCl following extraction from a simulated pill. 
Spectrum A is after hyperpolarisation transfer at earth’s magnetic field in the presence of 1 and 
parahydrogen whereas spectrum B is the sample at thermal equilibrium. The values indicated above 
the baseline indicate the enlargement factor of that part of the spectrum. The peaks marked α and β 
refer to the ortho- and meta-pyridyl 1H nuclei of 4-PMP respectively.  
 
The amount of 4-PMP.3HCl present in the tablet was also quantified by NMR via the use of a 
calibration plot (see SI). Although it has been reported by Eshuis and co-workers that a standard 
addition approach coupled with SABRE can be used to quantify the amount of nicotinamide, 
pyrazine, isoxazole and quinazoline present in a 16-component mixture,[8a] the same approach could 
not be utilised here. This is due to the requirement of needing to use an excess of TEA to 
compensate for the HPMC binder that was used in tablet manufacture. The amount of 4-PMP.3HCl 
determined to be in the tablet was only 23 mg (~ 22% of the weighed amount), which is a significant 
departure from the amount determined by GC. However, it must be noted that the analysis of the 
tablet by NMR required a higher concentration (~5 mg mL-1) whereas analysis by GC, which is 
significantly more sensitive, operated in the 𝜇𝜇g mL-1 regime, following dilution. Solubility was, 
therefore, suspected of being the underlying factor as to why the deduced amount of 4-PMP was ca. 
20% of the correct value. Thus, a further calibration plot was obtained that used D2O as the solvent. 
4-PMP.3HCl is very soluble in D2O and as such, it was found that TEA was not required. Resultantly, 
the amount of 4-PMP.3HCl was deduced as being 113.7 mg in the parent tablet; this value is not only 
comparable to that obtained by GC-MS but also reflects the amount that was weighed out originally. 
The quantification of NMR of 4-PMP.3HCl present in the simulated tablet highlights the significance 
of the solubility when determining the amount of active pharmaceutical ingredient (API) present in a 
sample. Evidently, the difference between the amount of 4-PMP.3HCl determined, using either 
methanol or D2O as a solvent, could have serious ramifications regarding safeguarding issues linked 
to drug abuse.  
Conclusions 
This paper describes the employment of SABRE to hyperpolarise BZP, 2-, 3- and 4-PMP, as well as the 
hydrochloride salts of BZP and 4-PMP. These studies revealed that BZP.HCl could not be polarised 
under the conditions employed, due to inability of the ligand to chelate to the metal centre of the 
SABRE catalyst employed, [Ir(IMes)(COD)Cl]. Addition of either 1.2 or 2 equivalents to either partially 
or completely freebase BZP still resulted in no enhancement of the signals in the 1H NMR spectrum 
due to hyperpolarisation transfer.  
2-, 3- and 4-PMP were also subjected to SABRE, and the resultant 1H NMR spectra highlighted that 
polarisation transfer had occurred with varying degrees of success. 2-PMP showed negligible 
enhancement (ortho-pyridyl protons observed to be emission, ε = ~1) whereas the ortho- and meta-
pyridyl protons of 4-PMP were enhanced by 313-fold and 267-fold respectively, following 
polarisation transfer at earth’s magnetic field. The ortho-pyridyl protons of 3-PMP possessed an 8-
fold enhancement. Optimisation of the magnetic field utilised for polarisation transfer could improve 
these enhancements further.  
The hyperpolarisation of the hydrochloride salt of 4-PMP was also explored. In the absence of TEA, 
4-PMP.3HCl showed no enhancement. However, the addition of increasing equivalents of TEA 
produced an observable enhancement, with a maximum of 300-fold being observed for 3 equivalent 
of TEA. The addition of further equivalents of TEA caused the enhancement to fall, with only a 20-
fold enhancement being observed for 10 equivalents of TEA.  
The effect of TEA on the enhancement observed for 4-PMP was probed similarly and the results 
from this study again showed a decrease drop in enhancement upon the addition of TEA, which 
mirrored that of 4-PMP.3HCl. After the addition of 7 equivalents of TEA, which is comparable to the 
4-PMP.3HCl in the presence of 10 equivalents of TEA, the enhancement of the ortho-pyridyl protons 
was only ~1-fold. This significant difference in enhancement (approximately 20-fold) is believed to 
be due to the difference in the chloride concentrations, with 4-PMP.3HCl possessing the higher 
chloride concentration.  
The approach developed herein was extended to polarise 4-PMP.3HCl within a simulated tablet 
sample. Although this approach requires the amount of 4-PMP.3HCl to be known, in order to add 
the corresponding amount of TEA to the sample to form the (polarisable) freebase, following 
polarisation transfer in earths’ field, an enhancement of 138-fold was obtained for the ortho-pyridyl 
protons of 4-PMP. The enhancement is lower than the freebase on its own, and this was because the 
amount of 4-PMP present was ca. 2 mg, instead of ca. 4.5 mg for the other 4-PMP.3HCl samples 
investigated herein. 
The amount of 4-PMP.3HCl in the simulated was quantified by GC-MS and NMR. The amount of 4-
PMP.3HCl determined by GC-MS matched well with the weighed value, whereas the amount 
determined by NMR when samples were solvated in CD3OD were considerably lower. This is 
believed to be due to issues surrounding solubility of 4-PMP.3HCl, despite being free-based due to 
the presence of TEA. Solubility is far improved in D2O, and as such a value of 113.7 mg was 
determined. The quantification of 4-PMP.3HCl by NMR highlights a potential safeguarding issue 
linked to drug abuse when determining the potency of a tablet based on the amount of API present.  
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